Roche to showcase the future of diagnostic solutions at EuroMedLab 10 - 14 April 2022 in Munich at ICM International Congress Center


  • New diagnostics solutions will be presented that help clinicians improve patient care and support healthcare systems.
  • Participants can join virtually or onsite to learn about timely healthcare topics related to value-based healthcare, digital health and diagnostic technologies. 
  • Study results from an evaluation of the newly launched AVENIO Tumour Tissue Comprehensive Genomic Profiling Kit for oncology research will be presented.
  • For the first time internationally, GenMark, a subsidiary within the Roche Diagnostics division, will showcase the ePlex® System portfolio.

Rotkreuz, 5 April 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it will be showcasing next generation diagnostics solutions that will deliver fast and accurate results to help clinicians  improve patient care and help reduce the healthcare burden at the 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicines (EuroMedLab) in Munich, Germany (rescheduled dates 10 - 14 April 2022).  These include the cobas® 5800 System that expands access to PCR testing with meaningful and timely results to more patients across the globe, and a new handheld glucose management device, the cobas® pulse, powered by the cobas® infinity edge suite, that equips healthcare professionals with expanded digital capabilities at the point of care. 

An evaluation of the recently launched AVENIO Tumour Tissue Comprehensive Genomic Profiling (CGP) Kit for oncology research will be presented.  The kit helps expand access to genomic profiling globally, supporting researchers in navigating the complex landscape of cancer research. The findings assess genomic results generated across multiple CGP workflows for variants that are known to cause and drive cancer.


Roche is committed to developing innovative solutions that equip healthcare professionals with the tools that allow for earlier diagnosis and more personalised treatment, optimising patient care and leading to better outcomes,

said Ann Costello, Global Head, Roche Diagnostics Solutions.

We are proud to work in partnership with healthcare professionals across many disease areas and disciplines to enable better healthcare decisions.


Roche will also host its very own highly interactive booth, where attendees can visit and experience how Roche is helping to improve healthcare. Highlights from the booth include an integrated diagnostics lab and data analytics tools that guide the decision-making process toward optimising lab operations, customer delivery, and overall lab performance in a targeted and efficient manner. There will also be a special interactive area at the booth highlighting Roche’s COVID-19 response.


Lab medicine has always played a key role in healthcare, as proven during the Covid-19 pandemic,

emphasised Moritz Hartmann, Global Head of Roche Information Solutions.

We are working with industry leaders worldwide on digital health solutions to facilitate data-driven decision-making in any setting.  This includes labs, clinics and homes with the ultimate goal to improve care for each patient and reduce inefficiencies in healthcare delivery.


Those unable to attend the congress in person will be able to view and engage  in the virtual  booth via an online portal, with Ro_Bot, a virtual character, as host: Roche EuroMedLab 2021. Those joining online will be able to follow key sessions via livestream, at no cost.

During the congress, Roche will facilitate discussions on the key topics in diagnostics today, including three educational workshops: 


Monday 11 April, 14:00–15:00    

EduW5: Pandemic Preparedness

Chair: Dr. Christian Simon, Roche Diagnostics

Fighting emerging pathogens – the COVID pandemic response in Germany

Professor Dr Andreas Weiser, Global Health & Infectious Diseases, at the Medical Center of the University of Munich

Diagnostic follow-up in a post vaccine setting

Professor Dr. Stefan Holdenrieder, Director of the Institute of Laboratory Medicine, German Heart Center of the Technical University Munich


Tuesday 12 April, 14:00-15:00      

EduW19: Diagnostic Innovation Drivers

Chair: Dr. Wim van der Helm, Roche Diagnostics

Use of mass spectrometry in clinical diagnostics

Professor Dr. Michael Vogeser, Germany

Timely and accurate differential diagnosis of patients with cognitive impairment

Professor Dr. Charlotte Teunissen, University Medische, Centra Amsterdam


Wednesday 13 April, 14:00-15:00      

EduW33: Diabetes and the heart

Chair: Dr, Paul van Haelst, Roche Diabetes Care

Early identification of heart failure in T2D: intervention for improving patient outcomes

Dr. Muthiah Veduganathan, MD. MPH, Harvard Medical School, Boston, USA

Integrated personal diabetes management

Professor Dr. Stephan Jacob, Praxis Für Prävention und Therapie, Villingen-Schwenningen, Germany

EuroMedLab Visual

EuroMedLab 2022 - April 10-14

Witness the future of innovation in diagnostics.

Join Roche on the journey to EML 2022, an exclusive window into the future of innovation in diagnostics.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit

All trademarks used or mentioned in this release are protected by law.

For further information:


Jonathan Parry, Roche Diagnostics Communications

Mobile: +41 79653 76 43

e-mail: [email protected]



Elizabeth Baxter, Roche Diagnostics Communications

Mobile: +1 925-523-8812

e-mail: [email protected]